Waters Corporation’s Fourth Quarter and Full-Year 2024 Financial Results: A Breakdown
MILFORD, Mass. – Waters Corporation, a global leader in laboratory sciences, recently reported its financial results for the fourth quarter and full-year 2024. The company announced impressive growth across various financial metrics, setting new records and surpassing expectations.
Fourth Quarter 2024 Sales
The fourth quarter sales for Waters Corporation came in at $873 million, marking a 6% increase as reported and an 8% growth in constant currency. The company’s instrument sales grew by 8%, while recurring revenue expanded by 9% in constant currency. This growth was observed in all three reported regions – the Americas, Europe, and Asia.
Pharma Segment Growth
The Pharma segment, a significant contributor to Waters Corporation’s revenue, experienced a robust 10% growth in constant currency. This growth was driven by stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and Asia.
Earnings Per Share (EPS)
GAAP EPS for the fourth quarter was reported at $3.88, while non-GAAP EPS stood at $4.10, representing a 13% growth over the previous year. The company’s strong operational performance and better-than-expected sales volume helped mitigate the impact of foreign exchange headwinds.
Full-Year 2024 Sales and Operating Cash Flow
For the full-year 2024, Waters Corporation’s sales reached $2,958 million, which was in line with the guidance and remained flat in organic constant currency. The company generated $762 million in operating cash flow and $744 million in free cash flow, representing 25% of full-year sales.
Impact on Individuals
As a consumer, the strong financial performance of Waters Corporation may not have a direct impact on your daily life. However, the company’s innovations in laboratory sciences contribute to advancements in various industries, including healthcare, pharmaceuticals, and food safety. These advancements can lead to improved diagnostics, new treatments, and safer food production methods, ultimately benefiting individuals around the world.
Impact on the World
From a global perspective, Waters Corporation’s financial results are a positive sign for the laboratory sciences industry. The company’s continued growth and innovation can lead to new technologies and solutions that address critical challenges in healthcare, pharmaceuticals, and other industries. These advancements can contribute to improved public health, increased productivity, and economic growth in various regions.
Conclusion
Waters Corporation’s fourth quarter and full-year 2024 financial results demonstrate the company’s commitment to delivering strong operational performance and growth, even in the face of foreign exchange headwinds. The company’s continued success in the laboratory sciences industry can lead to significant benefits for individuals and the world, including improved diagnostics, new treatments, and safer food production methods.
- Fourth quarter sales of $873 million, up 8% in constant currency
- Pharma segment growth of 10% in constant currency
- GAAP EPS of $3.88 and non-GAAP EPS of $4.10, up 13% over the previous year
- Full-year sales of $2,958 million, flat in organic constant currency
- Operating cash flow of $762 million and free cash flow of $744 million
- Continued growth and innovation in the laboratory sciences industry can lead to significant benefits for individuals and the world
